Browse
Submit Data
Databases
API
Help

Dataset Information

4 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Study on the mechanism of probiotics to improve opioid tolerance in cancer pain patients by regulating intestinal flora

ABSTRACT: Interventions: treatment group:tetralogy of viable bifidobacterium tablets;control group:No Primary outcome(s): Intestinal flora;Inflammatory cytokines;C-reactive protein;Erythrocyte sedimentation rate Study Design: Parallel

DISEASE(S): Cancer Pain

PROVIDER: 2694218 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Gene expression in Raw264.7 Cells following treatment with probiotics strains Lactobacillus acidophilus, Bacillus clausii and Bifidobacterium bifidum at MOI of 1 for 6 hours : NT (Time matched untreated cells) vs. Probiotics treated cells

Project description:Gene expression in RAW 264.7 cells on treatment with Lactobacillus acidophilus, Bacillus clausii and Bifidobacterium bifidum at MOI of 1 for 6 hours.

2019-05-31 | GSE98796 | GEO

Gene expression in THP-1 Cells following treatment with probiotics strains Lactobacillus acidophilus, Bacillus clausii and Bifidobacterium bifidum at MOI of 1 for 6 hours : NT (Time matched untreated cells) vs. Probiotics treated cells

Project description:Gene expression in THP-1 cells on treatment with Lactobacillus acidophilus, Bacillus clausii and Bifidobacterium bifidum at MOI of 1 for 6 hours.

2019-05-31 | GSE98798 | GEO

Mechanism of CsGPA1 in regulating cold tolerance of cucumber

Project description: Not available

| S-EPMC9265480 | biostudies-literature

Effect of probiotics on colorectal cancer in clinical trials

Project description:Interventions: Ten subjects receive probiotic product contained 10 million CFU in viable form 3 times a day for 6 months,Ten subjects receive probiotic product contained 10 million CFU in non viable form 3 times a day for 6 months, Ten subjects receive product without probiotic 3 times a day for 6 months;Active Comparator Dietary Supplement,Active Comparator Dietary Supplement,Placebo Comparator Dietary Supplement;probiotic products in viable form,probiotic products in non viable form,Control Primary outcome(s): reduceing of number of pathogens in gut at 6 months after intervention number of pathogens / Anova Study Design: Randomized

| 2727906 | ecrin-mdr-crc

Molecular mechanism for switching of P.falciparum invasion pathways into human erythrocytes

Project description:The malaria parasite, Plasmodium falciparum, exploits multiple ligand-receptor interactions, called invasion pathways, to invade the host erythrocyte. Strains of P.falciparum vary in their dependency on sialated red cell receptors for invasion. We show that switching from sialic acid-dependent to –independent invasion is reversible and depends on parasite ligand utilisation. Expression of P.falciparum reticulocyte-binding like homologue 4 (PfRh4) correlates with sialic acid-independent invasion and PfRh4 is essential for switching invasion pathways. Differential activation of PfRh4 represents a novel mechanism of invasion pathway control and provides P.falciparum with exquisite adaptability in the face of erythrocyte receptor polymorphisms and host immune responses. Keywords: Plasmodium falciparum, erythrocyte invasion, invasion pathways, EBA175, Rh4

2005-10-04 | GSE2878 | GEO

Probiotics ameliorate alveolar bone loss by regulating gut microbiota.

Project description: Not available

| S-EPMC8249787 | biostudies-literature

Astrocyte-targeting therapy rescues cognitive impairment caused by neuroinflammation via the Nrf2 pathway (ChIP-Seq)

Project description:Neuroinflammation is a common feature of neurodegenerative disorders such as Alzheimer's disease (AD). Neuroinflammation is induced by dysregulated glial activation, and astrocytes, the most abundant glial cells, become reactive upon neuroinflammatory cytokines released from microglia, and actively contribute to neuronal loss. Therefore, blocking reactive astrocyte functions is a viable strategy to manage neurodegenerative disorders. However, factors or therapeutics directly regulating astrocyte subtype remain unexplored. Here, we identified transcription factor NF-E2-related factor 2 (Nrf2) as a therapeutic target in neurotoxic reactive astrocytes upon neuroinflammation. We found that the absence of Nrf2 promoted the activation of reactive astrocytes in the brain tissue samples obtained from AD model 5xFAD mice, whereas enhanced Nrf2 expression blocked the induction of reactive astrocyte gene expression by counteracting NF-kB subunit p65 recruitment. Neuroinflammatory astrocytes robustly upregulated genes associated with type I interferon and the antigen-presenting pathway, which were suppressed by Nrf2 pathway activation. Moreover, impaired cognitive behaviors observed in AD mice were rescued upon ALGERNON2 treatment, which potentiated Nrf2 pathway and reduced the induction of neurotoxic reactive astrocytes. Thus, we highlight the potential of astrocyte-targeting therapy by promoting the Nrf2 pathway signaling for neuroinflammation-triggered neurodegeneration.

2023-08-07 | GSE237423 | GEO

Astrocyte-targeting therapy rescues cognitive impairment caused by neuroinflammation via the Nrf2 pathway ( nascent RNA-Seq )

2023-08-07 | GSE237422 | GEO

Study of the protective effect of D-Lactate-producing probiotics on CNS pathology

Project description:Dendritic cells (DCs) control the generation of self-reactive pathogenic T cells. Thus, DCs are attractive therapeutic targets for autoimmune diseases. Using single-cell and bulk transcriptional and metabolic analyses in combination with cell-specific gene perturbation studies we identified a negative feedback regulatory pathway that operates in DCs to limit immunopathology. Specifically, we found that lactate, produced by activated DCs and other immune cells, boosts NDUFA4L2 expression through a mechanism mediated by HIF-1a. NDUFA4L2 promotes mitochondrial fitness in DCs, limiting the production of mitochondrial reactive oxygen species that activate XBP1-driven transcriptional modules involved in the control of pathogenic autoimmune T cells. Moreover, we engineered a probiotic that produces lactate and suppresses T-cell autoimmunity in the central nervous system via the activation of HIF-1a/NDUFA4L2 signaling in DCs. In summary, we identified a novel immunometabolic pathway that regulates DC function, and developed a synthetic probiotic for its therapeutic activation via the gut-brain axis.

2023-08-18 | GSE188503 | GEO

Assessment of Potentially Inappropriate Prescribing of Opioid Analgesics Requiring Prior Opioid Tolerance.

Project description: Not available

| S-EPMC7160686 | biostudies-literature